Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials.

Gili Kenet,Thomas Moulton,Brian M Wicklund,Sanjay P Ahuja,Miguel Escobar,Johnny Mahlangu

Journal of blood medicine（2023）

引用 0|浏览10

暂无评分

摘要

Treatment with octocog alfa prophylaxis appeared to have a favorable risk-benefit profile compared with rFVIII-FS and thus could be an effective and improved alternative strategy for individualized treatment for children, adolescent and adult patients with severe hemophilia A currently on rFVIII-FS treatment.

查看译文

关键词

bleed outcomes,octocog alfa,leopold clinical trials,prophylaxis,sucrose-formulated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要